Latest Breaking News On - Clinician global impression - Page 5 : comparemela.com

Vistagen Presents Fasedienol (PH94B) Safety and Exploratory Efficacy Data from Phase 3 Open-Label So

Favorable long-term, open-label treatment data from nearly 500 patients in real-world setting suggest that patient-tailored, as-needed administrations of fasedienol over time were safe and well-toleratedPositive exploratory fasedienol efficacy data measured by the Liebowitz Social Anxiety Scale (LSAS) demonstrated c.

United statesShawn singhNate hitchingsMark mcpartlandExchange commissionAmerican society for clinical psychopharmacologyLiebowitz social anxiety scaleAmerican societyClinical psychopharmacologyClinician global impressionPatient global impressionChief executive officerAnnual reportQuarterly reportVice presidentInvestor relations

Ligand Reports First Quarter 2023 Financial Results

2023 Financial Guidance Raised Conference Call Begins at 4:30 p.m. Eastern Time Today . | May 4, 2023

Acrotech biopharmaValentino stellaTodd davisUniversity of kansa higuchi biosciences centerUniversity distinguished professorGilead sciencesExchange commissionLigand pharmaceuticalsOur pelican expression technologyLigand pharmaceuticals incorporatedBaxter internationalAnebulo pharmaceuticals nasdaqWorld congressPelican expression technologyViking therapeuticsRecent business

Bionomics Announces the Completion of Enrollment in Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)

Bionomics Announces the Completion of Enrollment in Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomSouth australiaUnited statesConnor bernsteinviceSpyros papapetropoulosRelationskevin gardnerExchange commissionInvestor centerBionomics or companyMerck co incBionomics ltdCorporate developmentCompany annual report on formBionomics limited nasdaqPost traumatic stress disorderSocial anxiety disorder

Endo Provides Top-Line Results from Phase 2 Study of Collagenase Clostridium Histolyticum (CCH) in Participants With Plantar Fibromatosis

/PRNewswire/ Endo International plc (OTC: ENDPQ) today announced top-line results from its Phase 2 clinical study of collagenase clostridium histolyticum.

United statesJamesp tursiJosephm caporussoPrnewswire endo internationalExchange commissionCopies of the companyCompany investor relations departmentEndo internationalGlobal research development at endoFoot function indexSpain scaleClinician global impressionExecutive vice presidentGlobal researchRestriction scalePrivate securities litigation reform act

Endo International plc: Endo Provides Top-Line Results from Phase 2 Study of Collagenase Clostridium Histolyticum (CCH) in Participants With Plantar Fibromatosis

DUBLIN, March 13, 2023 /PRNewswire/ Endo International plc (OTC: ENDPQ) today announced top-line results from its Phase 2 clinical study of collagenase clostridium histolyticum (CCH) in participants

United statesDennis riedlJamesp tursiJosephm caporussoPrnewswire endo internationalExchange commissionCopies of the companyCompany investor relations departmentGlobal research development at endoFoot function indexSpain scaleClinician global impressionExecutive vice presidentGlobal researchRestriction scalePrivate securities litigation reform act